Decision: Favourable
Study Title:
A Phase 1/1b Open-Label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors
NREC Code:
23-NREC-CT-024
Decision:
Favourable
Meeting Date:
24/03/2023
Study Type:
CT application
Principal Investigator:
Prof John Crown
PI Institution:
St Vincent's University Hospital
Sponsor:
Kinnate Biopharma Inc